Резистентность к пероральным антитромбоцитарным препаратам (ацетилсалициловая кислота и клопидогрел) при стентировании коронарных артерий у больных со стабильными формами ИБС
Диссертация
Комбинированная терапия является одним из ключевых факторов предупреждения тромбоза стентов в ближайшем и отдаленном периоде у больных ИБС после коронарной ангиопластики. На основании различных данных можно предполагать, что одной из причин раннего тромбоза коронарных стентов является наличие резистентности к антитромбоцитарным препаратам. Согласно современным данным, более 30% пациентов имеют… Читать ещё >
Список литературы
- Айнетдинова Д.Х., Удовиченко А. Е., Сулимов В. А. Резистентность к антитромбоцитарным препаратам у больных с острым коронарным синдромом без подъема сегмента ST.// Кардиология 2008- № 6: с. 3539.
- Баркаган З.С., Момот А. П. Основы диагностики нарушения гемостаза. М.: Ньюдиамед-АО, 1999.- 224 страниц
- Бокерия Л.А., Керен М. А., Ключников И. В. Оптимизация результатов чрескожного коронарного вмешательства у больных ИБС с ожирением. // Креативная кардиология. 2008. — № 2. — С. 46−57.
- Бузиашвили, Ю.И. Оправдан ли стандартный подход к антиагрегантной терапии при коронарном стентировании у больных ИБС.//Креативная кардиология. -2010. -№ 1.- С. 111−115.
- Волков В.И., Рябуха В. В., Запровальная O.E. Диагностика резистентности к аспирину у больных с ишемической болезнью сердца.// Украинский кардиологический журнал. 2006. — № 3. С. 36−40.
- Грацианский H.A. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения.// Атеротромбоз. -2010. -№ 1.~ С. 2−54.
- Методики клинических лабораторных исследований. Справочное пособие под руководством Меньшикова В. В. М.: Лабора, 2008. — С. 156−157.
- Панченко Е.П., Кропачева Е. С. Рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза.// М.: Институт клинической кардиологии им. А. Л. Мясникова ФГУ РКНПК1. Росмедтехнологий.
- Панченко Е.П. Концепция атеротромбоза основа сердечно-сосудистых заболеваний// РМЖ. — 2005 — том 13. — № 7. — С. 35−39.
- Панченко Е.П. Атеротромбоз: механизмы развития и реально проводимая терапия// Атеротромбоз. 2008. — № 1. — С. 22−26.
- Aleil В. Flow cytometric analysis of intraplatelet VASP phosphorilation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases.// J. Thromb. Haemost. 2005. — Vol. 3.- P. 85−92.
- Ajzenberg N., Aubry P., Huisse M.G., et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis a case control study.// J Am Coll Cardiol. 2005. — Vol. 45. — P. 1753−1756.
- Angiolillo D.J., Bernardo E., Ramirez C., Sabate M., et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. //Thromb Res. 2005. — Vol. 115. — P. 101−108.
- Angiolillo D.J., Bernardo E., Ramirez C. et al. Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment.// Diabetes. 2005. — Vol. 54. — P. 24 302 435.
- Angiolillo D. J, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. //Eur Heart J. 2010. — Vol.31. — P. 17−28.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients// BMJ. 2002. — Vol. 324. — P. 71−86.
- Bliden K.P., Tantry U., Zaman K., Hayes K. High platelet reactivity is a risk factor for post-discharge ischemic complications following elective coronary stenting. //J AmColl Cardiol. 2005. — Vol.45. — P. 33.
- Bonello L. Tailored Clopidogrel loading dose according to platelet reactivity Monitoring to prevent acute and subacute stent thrombosis. //Am J Cardiol. -2009.-Vol. 103.-P. 5−10.
- Buonamici P., Marcucci R. Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis.//J Am Coll Cardiol. -2007.-Vol. 49.-P. 2312−2317.
- CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)// Lancet. -1996.-Vol.348.-P. 1329−1339.
- Chen W., Lee P., Weyt N. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment // J Am Coll Cardiol. 2004. -Vol.43.-P. 1122−1126.
- Cipollone F., Rocca B., Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis.// Arterioscler Thromb. Vase. Biol. 2004. -Vol. 24(2).-P. 246−255.
- Combescure C. Clinical implications of clopidogrel non-response in cardiovascular patients a systematic review and meta-analisys.// J. Thromb Haemost. 2010 — Vol. 8. — P. 923−933.
- Csiszar A. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. //Prostaglandins Leukot Essent Fatty Acids. -2002.-Vol.66.-P. 557−558.
- Cuisset T., Frere C., Quilici J., et al. Glicoprotein IlbUIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective randomized study. //J Am Coll Cardiol Intv. 2008. — Vol.1. — P. 649−653.
- Effect of Clopidogrel in addition to aspirin in patients with acute coronary syndroms without ST elevation. The CURE Trial investigators. //N. Engl J Med. 2001. — Vol.345. — P. 494−502.
- Ferguson A.D., Dokainish H., Lakkis N. Aspirin and Clopidogrel response variability: review of the published literature.// Tex Heart Inst J. 2008 -Vol.35(3).-P. 313−320.
- Geiger J. Monitoring of Clopidogrel Action: Comparison of Methods.// Clin. Chem. 2005. — Vol.51. — P. 957−965.
- Ghannudi S. E., Ohlmann P., Meyer N., Wiesel M.L., Radulescu B., Chauvin M., Bareiss P., Gachet C., Morel O. Impact of P2Y 12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by
- Percutaneous Coronary Angioplasty: A Prospective Registry.// J Am Coll Cardiol Intv. 2010. — Vol.3. — P. 648−656.
- Gremmel T., Steiner S., Seidinger D., et al. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. //Heart. 2010. -Vol. 96. -P. 186−189.
- Gori A.M., Marcucci R., Migliorini A., et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and Clopidogrel in patients with drug-eluting stents.// J Am Coll Cardiol. 2008. — Vol.52(9). — P. 734−739.
- Guidelines on platelet function testing.// J Clin Pathol. 1988. — Vol.41 (12).-P. 1322−1330.
- Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. // Eur. Heart J. 2007. — Vol.28. — P. 1598−1660.
- Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).// Eur Heart J. -2010.-Vol.9.-P. 1645−1664.
- Gum P.A., Kottke-Marchant K, Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.// J. Amer. Coll. Cardiol. -2003.-Vol.41.-P. 961−965.
- Gurbel P.A., Bliden K.P., Hiatt B.L. Clopidogrel for coronary stenting: response variability drug resistance and the effect of pretreatment platelet reactivity.// Circulation. 2003. — Vol.107. — P. 2908−2913.
- Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. //J Am Coll Cardiol. 2005. -Vol.46.-P. 1827−1832.
- Gurbel P.A., Bliden K.P., Guyer K., Cho P.W. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.// J Am Coll Cardiol. 2005. — Vol.46. — P. 1820−1826.
- Gurbel P.A., Bliden K.P., Zaman K.A., Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the CLEAR PLATELETS Study.//Circulation.-2005.-Vol.111.-P. 1153−1159.
- Gurbel P.A., Bliden K.P., Law W.C., Tantry U.S. Clopidogrel resistance: implications for coronary stenting. //Curr Pharm Des. 2006. — Vol.12. — P. 1261−1269.
- Gurbel P.A. Michelson A.D. Platelet function monitoring in patients with coronary artery disease.// J Am Coll Cardiol. 2007. — Vol.50 (19). — P. 1822−1834.
- Gurbel P.A. Bliden K.P. Butler K. et al. Randomised Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelate Effects of Ticagrelor Versus Clopidogrel.// Circulation.- 2009. Vol.120. — P. 25 772 585.
- Gurbel P. A Clopidogrel resistance.// J Inv Cardiol. 2009. — Vol.56. — P. 235−237.
- Gurbel P.A., Bliden K.P., Butler K., et al. Response to ticagrelor in Clopidogrel nonresponders and responders and the effect of switching therapies: The RESPOND study.// Circulation. 2010. — Vol.121. — P. 11 881 199.
- Hankey J., Eikellboom JW. Aspirin resistance //BMJ. 2004. — Vol.328. — P. 474−479.
- Harrison P. Screening for aspirin responsiveness after transient ischemic attack and stroke. //Stroke. 2005. — Vol.36. — P. 1001−1011.
- Hart R.G., Leonard A.D., Talbert R.L. et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease // Pharmacother. -2003. Vol.23. — P. 579−584.
- Hulot J.S. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. //Blood. -2006. Vol.108. — P. 2244−2247.
- Hulot J-S, Collet J-P, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration.// J Am Coll Cardiol. 2010. -56:134−143.
- ISIS-2. Collaborative Group// Lancet. 1988. — Vol.332. — P. 349−360.
- Jaremo P., Lindahl T. L, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. //J Intern Med. 2002. -Vol.252.-P. 233−238.
- Law W.C., Gurbel P. A .et al. Atorvastatin reduses the ability of clopidogrel to inhibit plateletaggregation: a new drug-drug interaction.// Circulation. -2003.-Vol.107.-P. 32−41.
- Lee P., Chen W., Ng W., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease // Am J Med. 2005. — Vol.118. — P. 723−727.
- Lepantalo A., Virtanen K.S., Heikkila J., Lassila R. Limited early antiplatelet effect of 300 mg Clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions. //Eur Heart J. 2004. -Vol.25.-P. 476−483.
- Lev E.I., Patel R.T., Maresh K.J., Granada J., Delao T., et al. Aspirin and Clopidogrel drug response in patients undergoing percutaneous coronary interventions: the role of dual drug resistance.// J Am Coll Cardiol. 2006. -Vol.47.-P. 27−33.
- Lordkipanidze M. Comparison of 4 tests to assess inhibition of platelet function by clopidogrel//Eur .Heart J. 2008. — Vol.29. — P. 2877−2885.
- Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P450 2C19 genetic polymorphism and the response to prasugrel.//Circulation. 2009. — Vol.119. -P. 2553−2560.
- Mega J.L. CYP2C19*2 Genetic Variants and Clinical Outcomes With Clopidogrel: Meta-Analysis.// Circulation. 2009. — Vol.120. — P. 598−599.
- Mehta S.R. CURRENT OASIS 7 Investigators. Dose comparisons of Clopidogrel and aspirin in acute coronary syndromes.// N Engl J Med.-September 2010. Vol.363(10). — P.930−942.
- Mobley J.E., Bresee S.J., Craft R.M., Snider C.C. Freqvency of nonresponce antiplatelet activity of Clopidogrel during pretreatment for cardiac catheterization.// Am J Cardiol. 2004. — Vol.93. — P. 456−458.
- Muller I., Besta F., Schulz C. Prevalence of Clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. //Thromb Haemost. 2003. — Vol.89. — P. 783−787.
- Price M.J. Berger P.B. Evaluation of individualized Clopidogrel therapy after stent implantation in patient with high residual platelet reactivity: design and rationale of the GRAVITAS trial.// Am Heart J. 2009. — Vol.157. — P. 818 824.
- Przyklenk K. Cardioprotection with adenosine. //Br J Pharmacol. 2005. -Vol.12.-P. 699−700.
- Pulcinelli F.M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P.P., Violi F. Inhibition of platelet aggregation by aspirin progressively decreasesin long-term treated patients. //J Am Coll Cardiol. 2004. — Vol.43(6). — P. 979−984.
- Saw J. Clopidogrel for the Reduction of Events During Observation Investigators. //Circulation. 2003. — Vol.108. — P. 921−924.
- Schomig A. Ticagrelor is there need for a new player in the antiplatelet field?// N Engl J Med. — 2009. — Vol.361. — P. 1108−1111.
- Serebrunay V.L. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. //Atherosclerosis. 2001. — Vol.159. — P. 239−241.
- Shuldiner A.R., O Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. //JAMA. 2009. — Vol.302. P. 849−857.
- Sibbing D. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.// EurHeart J. -2009.-Vol.30.-P. 916−922.
- Sibbing D., Braun S., Morath T., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. //J Am Coll Cardiol. 2009 — Vol.53(10). — P.849−856.
- Siller-Matula J.M., Jilma B. Pharmacokinetic, pharmacodinamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. //Br J Pharmacol. -2009-Vol.12.-P. 1264−1269.
- Simon T. Genetic Determinants of Response to Clopidogrel andrvxrop/^lllpl* CT/pnfr //M"Cr, rr1 TA/fo^ OOOO Dui"j v do^uidi v v^iiio. / /1 > j ivilu. — jy. — v vji.juu. — x. u / .
- Snoep J.D. Clopidogrel nonresponsiveness in patient undergoing percutaneous intervention with stenting: a systematic review and metaanalysis.// Am Heart J. 2007. — Vol.154. — P. 221−231.
- Steinhubl S.R. Early and sustained dual oral antiplatelet therapy followingpercutaneous coronary intervention: a randomized controlled trial //JAMA. -2002. Vol.288. — P. 2411 — 2420.
- Steinhubl S.R. Genotyping, Clopidogrel Metabolism and the Search for the Therapeutec Window of Thienopyridines.// Circulation. 2010. — Vol.121. P. 481−483.
- Stone G.W. Ticagrelor in ACS redefining a new standard of care?// Lancet. -2010. Vol.14.-P. 1636−1642.
- Storey R.F. New developments in antiplatelet therapy. //Eur Heart J Supplements. 2008. — Vol.10. — P. 30−37.
- Szczeklik A. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. //Arterioscler Thromb Vask Biol. 1996. — Vol.16. -P. 948−954.
- Szczeklik A. et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.//J Am Coll Cardiol. 1999. — Vol.33. — P. 1286−1293.
- Trenk D. Cytochrome P450 2C19 681GA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous intervention with stents. //J Am Coll Cardiol. 2008. — Vol.51. — P. 1925−1934.
- Trial to Assess the Effects of SCH530348 in preventing Heart Attack and Stroke in Patients With Acute Syndrome.// Thrombosis. 2011 — Vol.2 -P. 739−749.
- Von Beckerath N., Kastrati A., Wieczorek A., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.// Eur Heart J. 2007. -Vol.28(15). — P.1814−1819.
- Wiviott S.D. TRITON-TIMI 38 Investigators.//Circulation. 2008. -Vol.118.-P. 1626−1636.